Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ferring Pharmaceuticals
Biotech
Ferring terminates fertility trials after ‘portfolio assessment’
Two trials testing the pairing of choriogonadotropin beta with Rekovelle have been terminated as part of “a broader portfolio assessment.”
Darren Incorvaia
Apr 2, 2026 2:00pm
Ferring's research site closure signals shift from internal R&D
Apr 11, 2023 11:22am
Ferring shuts down U.S. research institute, cutting 89 staffers
Mar 28, 2023 9:52am
Finch continues to pinch pennies to stretch cash into 2025
Mar 24, 2023 11:10am
FDA committee votes for Ferring's C. difficile therapy
Sep 23, 2022 10:15am
I-Mab's IL-6 drug hits goal in ulcerative colitis phase 2
Apr 26, 2021 8:45am
